Familial hypercholesterolaemia in South Africa: A reminder

Ad, Marais; Blom, Dirk; Raal, Frederick J.

doi:10.7196/samj.2021.v111i8.15782

Cited by 2 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most cholesterol-lowering medicines decrease blood cholesterol levels with few side effects such as headache, dizziness and myalgia (Raal et al 2011 ). Experienced by 5% to 10% of patients undergoing HMG-CoA reductase inhibitor therapy, also known as statin therapy, myalgia is one of the most frequently encountered side effects (Marais 2016 ). However, the type and severity of side effects vary from person to person (Raal et al 2011 ).…”

Section: Introductionmentioning

confidence: 99%

“…Due to side effects and the desire to be on natural supplements, such as the complementary and alternative medicines, patients may seek an alternative treatment available at the pharmacy (Marais 2016 ). A case report of a 49-year-old man taking a statin for the past 3 years showed improved cholesterol levels and eventually reaching an acceptable cholesterol range.…”

Section: Introductionmentioning

confidence: 99%

“…However, the patient continued to experience myalgia and a pharmacist advised discontinuing statin therapy and starting an over the counter product containing a natural supplement. After being on over-the-counter natural supplements for nearly 2 months, a significant increase in LDL was noted (Marais 2016 ). Recommending a natural cholesterol lowering supplement (NCLS) product with insufficient evidence can be harmful to a patient.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A scoping review on natural cholesterol lowering supplements sold in South African pharmacies

Lee,

Khan,

Vally

et al. 2024

Health SA Gesondheid

View full text Add to dashboard Cite

Background: Dyslipidaemia is defined as elevated total or low-density lipoprotein (LDL) levels or low levels of high-density lipoprotein (HDL). Patients may often make use of natural cholesterol lowering supplements (NCLSs) available at the pharmacy; however, limited information on these supplements is readily available. Pharmacists should be knowledgeable about NCLSs to ensure that the use of these supplements is supported by evidence and to provide appropriate advice to patients for desirable therapeutic outcomes.Aim: This study aimed to identify the NCLSs being sold in South African pharmacies and review the scientific evidence for each of the ingredients in these NCLSs.Methods: Seventeen NCLS products were identified, and the Joanna Briggs Institute (JBI) scoping review methodology was used to conduct a literature review of NCLSs.Results: From the ingredients reviewed it is evident that co-enzyme Q10, probiotics and sterols have sufficient evidence supporting their use. However, there is still limited scientific evidence available to validate the remaining ingredients.Conclusion: Further research on NCLSs will provide practising pharmacists and practitioners with a guide of the evidence available on the various ingredients in NCLSs.Contribution: This study provides a review of the available literature on the NCLSs being sold in the pharmacies across South Africa to provide pharmacists with a collated document of the evidence behind these popular supplements to assist them in making evidence based informed decision regarding natural products for cholesterol.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A scoping review on natural cholesterol lowering supplements sold in South African pharmacies

Lee,

Khan,

Vally

et al. 2024

Health SA Gesondheid

View full text Add to dashboard Cite

show abstract

“…Given the increasing burden of non-communicable diseases, and in particular atherosclerotic cardiovascular disease, in SA, the guideline from the Council for Medical Schemes should promote appropriate assessment and treatment. The PMB-X 2023 guideline makes it especially difficult for individuals with FH, a particularly common condition in SA, [4] to receive treatment, and does not promote wellestablished and proven LDL-C targets for other individuals.…”

mentioning

confidence: 99%